THE SPECIFIC FEATURES OF THE PHASE I OF CLINICAL INVESTIGATIONS OF DRUGS
Abstract
This article discusses the possibility of clinical research of drugs, identifies the specific features of the phase I of clinical investigations.
About the Authors
A. Y. Savchenko
First MSMU named after I.M. Sechenov
Russian Federation
Russian Federation
A.Yu. Savchenko, PhD, deputy director of innovative development of the Research institute of pharmacy
G. V. Ramenskaya
First MSMU named after I.M. Sechenov
Russian Federation
Russian Federation
G.V. Ramenskaya, Doctor of pharmacy, prof., head of the chair of pharmaceutical and toxicological chemistry, director of the Research institute of pharmacy
V. G. Kukes
First MSMU named after I.M. Sechenov
Russian Federation
Russian Federation
V.G. Kukes, MD, prof., head of the chair of clinical pharmacology and internal medicine propaedeutics
References
1. Kola I, Landis J. Can the industry reduce attrition rates? // Nature Rev. Drug Disc. — 2004. — Vol. 3. — 711 p.
2. Lesko L, Atkinson A. Use of biomarkers and surrogate endpoints in drug development // Ann. Rev. Pharmacol. Toxicol. — 2001. — Vol. 41. — P. 347–366.
3. Bioavailability and bioequivalence // CPMP/EWP/QWP. — 1998. — 1401 p.
4. Shah R. QT interval in drug development // Br. J. Clin. Pharmacol. — 2002. — Vol. 54. — P. 188–202.
5. Estimating the safe starting dose for healthy volunteers. — FDA, 2005.
6. Toxicokinetics and exposure in toxicology studies // CPMP/ICH. — 1995. — 384 p.
7. Declaration of Helsinki. — World Medical Association, 1996.
8. Sibille M et al. Is phase 1 still safe? // Br. J. Clin. Pharmacol. — 2006. — Vol. 62. — P. 502–503.
Review
Views:
225
Email this article 